Hubei Biocause Heilen Pharmaceutical Co., Ltd.
SZSE:301211.SZ
21.24 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2025 Q1 | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 114.446 | 111.871 | 92.127 | 102.18 | 137.484 | 119.132 | 136.687 | 212.472 | 193.287 | 169.255 | 105.281 | 112.13 | 128.246 | 122.279 | 141.519 | 155.848 | 120.977 | 170.363 | 128.537 | 225.681 | 68.343 |
| Cost of Revenue
| 89.067 | 84.252 | 78.235 | 70.343 | 85.712 | 76.659 | 75.541 | 114.865 | 131.01 | 126.107 | 72.578 | 81.023 | 90.077 | 89.748 | 93.266 | 109.232 | 69.808 | 89.837 | 61.76 | 146.943 | 73.471 |
| Gross Profit
| 25.38 | 27.618 | 13.892 | 31.837 | 51.771 | 42.473 | 61.147 | 97.607 | 62.277 | 43.148 | 32.703 | 31.107 | 38.17 | 32.53 | 48.252 | 46.616 | 51.169 | 80.526 | 66.777 | 78.739 | -5.129 |
| Gross Profit Ratio
| 0.222 | 0.247 | 0.151 | 0.312 | 0.377 | 0.357 | 0.447 | 0.459 | 0.322 | 0.255 | 0.311 | 0.277 | 0.298 | 0.266 | 0.341 | 0.299 | 0.423 | 0.473 | 0.52 | 0.349 | -0.075 |
| Reseach & Development Expenses
| 6.579 | 6.669 | 6.973 | 7.917 | 10.942 | 17.113 | 14.717 | 13.097 | 7.118 | 4.739 | 5.508 | 4.972 | 4.625 | 5.89 | 4.534 | 4.811 | 2.788 | 10.436 | 6.563 | 2.988 | 2.988 |
| General & Administrative Expenses
| 10.436 | -16.76 | 23.412 | -4.219 | 9.603 | -22.514 | 29.478 | -3.894 | 9.757 | 4.411 | 25.415 | 0.251 | 11.743 | -0.813 | 11.423 | 4.604 | 8.793 | -55.194 | 17.973 | 16.044 | 16.044 |
| Selling & Marketing Expenses
| 6.171 | 0.911 | 8.738 | 4.521 | 5.88 | 6.612 | 4.099 | 6.79 | 6.583 | 1.115 | 4.56 | 2.804 | 6.426 | 3.568 | 2.934 | 0.679 | 4.791 | 4.017 | 4.665 | 2.763 | 2.763 |
| SG&A
| 16.608 | -15.849 | 32.15 | 13.607 | 15.81 | 8.859 | 33.578 | 2.896 | 16.34 | 3.471 | 29.975 | 3.055 | 18.169 | 2.754 | 14.357 | 6.439 | 12.762 | -51.177 | 22.638 | 18.779 | 18.779 |
| Other Expenses
| -10.324 | 18.875 | -27.059 | -0.227 | -0.017 | 1.527 | -0.236 | 0.028 | -0.174 | -20.181 | 0.011 | 0.049 | -0.103 | 0.044 | -1.875 | -119.318 | -81.201 | 28.34 | -0.05 | 11.329 | -48.67 |
| Operating Expenses
| 12.863 | 9.694 | 12.064 | 21.524 | 26.752 | 24.445 | 35.582 | 27.349 | 24.669 | -11.971 | 21.739 | 19.779 | 19.056 | 10.725 | 12.325 | -119.318 | -81.201 | 26.739 | 21.298 | 11.329 | -48.67 |
| Operating Income
| 12.516 | 17.924 | 1.828 | 10.313 | 25.019 | 18.028 | 37.377 | 85.679 | 48.112 | 55.119 | 28.197 | 31.564 | 33.846 | 24.885 | 38.095 | 36.53 | 39.777 | 48.837 | 40.383 | 90.068 | 19.673 |
| Operating Income Ratio
| 0.109 | 0.16 | 0.02 | 0.101 | 0.182 | 0.151 | 0.273 | 0.403 | 0.249 | 0.326 | 0.268 | 0.281 | 0.264 | 0.204 | 0.269 | 0.234 | 0.329 | 0.287 | 0.314 | 0.399 | 0.288 |
| Total Other Income Expenses Net
| -0.016 | -0.086 | -0.133 | 26.248 | -0.017 | -2.136 | -0.236 | 0.028 | -0.174 | -1.241 | 0.011 | 0.049 | -0.103 | 0.044 | -0.146 | -0.001 | 0 | -0.157 | -0.05 | -0.121 | -35.198 |
| Income Before Tax
| 12.5 | 17.838 | 1.695 | 36.562 | 44.324 | 32.03 | 37.141 | 85.707 | 47.938 | 53.879 | 28.208 | 31.613 | 33.743 | 24.929 | 37.949 | 36.53 | 39.777 | 48.68 | 40.333 | 89.946 | 19.673 |
| Income Before Tax Ratio
| 0.109 | 0.159 | 0.018 | 0.358 | 0.322 | 0.269 | 0.272 | 0.403 | 0.248 | 0.318 | 0.268 | 0.282 | 0.263 | 0.204 | 0.268 | 0.234 | 0.329 | 0.286 | 0.314 | 0.399 | 0.288 |
| Income Tax Expense
| 2.174 | 0.953 | -4.47 | 5.447 | 6.942 | 0.428 | 5.665 | 12.591 | 8.015 | 6.637 | 4.056 | 5.179 | 5.778 | 2.632 | 6.594 | 5.061 | 3.248 | 10.134 | 2.862 | 15.109 | 2.455 |
| Net Income
| 10.326 | 16.886 | 6.166 | 31.114 | 37.382 | 31.601 | 31.476 | 73.116 | 39.923 | 47.242 | 24.152 | 26.434 | 27.965 | 22.297 | 31.355 | 31.469 | 36.529 | 38.546 | 37.471 | 74.837 | 17.218 |
| Net Income Ratio
| 0.09 | 0.151 | 0.067 | 0.305 | 0.272 | 0.265 | 0.23 | 0.344 | 0.207 | 0.279 | 0.229 | 0.236 | 0.218 | 0.182 | 0.222 | 0.202 | 0.302 | 0.226 | 0.292 | 0.332 | 0.252 |
| EPS
| 0.04 | 0.059 | 0.021 | 0.11 | 0.13 | 0.11 | 0.11 | 0.25 | 0.14 | 0.17 | 0.084 | 0.092 | 0.1 | 0.077 | 0.11 | 0.15 | 0.17 | 0.13 | 0.17 | 0.21 | 0.08 |
| EPS Diluted
| 0.04 | 0.059 | 0.021 | 0.11 | 0.13 | 0.11 | 0.11 | 0.25 | 0.14 | 0.17 | 0.084 | 0.092 | 0.1 | 0.077 | 0.11 | 0.15 | 0.17 | 0.13 | 0.17 | 0.21 | 0.08 |
| EBITDA
| 12.548 | 17.968 | 1.753 | 41.964 | 44.387 | 37.503 | 37.211 | 91.291 | 53.507 | 37.282 | 10.964 | 11.328 | 19.114 | 14.339 | 41.579 | 41.342 | 44.589 | 54.087 | 41.974 | 42.668 | 68.343 |
| EBITDA Ratio
| 0.11 | 0.161 | 0.019 | 0.411 | 0.323 | 0.315 | 0.272 | 0.43 | 0.277 | 0.22 | 0.104 | 0.101 | 0.149 | 0.117 | 0.294 | 0.265 | 0.369 | 0.317 | 0.327 | 0.189 | 1 |